UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/350/0.1/15.01.25 | Real-time BOERSE MUENCHEN 11:42:13 2024-06-21 am EDT | ||
| 12.39 EUR | -2.29% |
|
| Current month | +12.61% | ||
| 1 month | +18.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 12.39 | -2.29% |
| 24-06-20 | 12.68 | +2.18% |
| 24-06-19 | 12.41 | -0.08% |
| 24-06-18 | 12.42 | -4.02% |
| 24-06-17 | 12.94 | -4.99% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 11:42 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC49PZ |
| ISIN | DE000HC49PZ8 |
| Date issued | 2023-02-20 |
| Strike | 350 $ |
| Maturity | 2025-01-15 (208 Days) |
| Parity | 10 : 1 |
| Emission price | 4.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.85 € |
|---|---|
| Lowest since issue | 3.39 € |
| Spread | 0.07 € |
| Spread % | 0.57% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Warrants
- Warrant
